- Home
- CGO vs AGEN Comparison
CGO vs AGEN Comparison
Compare CGO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- AGEN
- Stock Information
- Founded
- CGO 2004
- AGEN 1994
- Country
- CGO United States
- AGEN United States
- Employees
- CGO N/A
- AGEN N/A
- Industry
- CGO Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGO Finance
- AGEN Health Care
- Exchange
- CGO Nasdaq
- AGEN Nasdaq
- Market Cap
- CGO 121.2M
- AGEN 142.8M
- IPO Year
- CGO N/A
- AGEN 2000
- Fundamental
- Price
- CGO $12.28
- AGEN $4.25
- Analyst Decision
- CGO
- AGEN Buy
- Analyst Count
- CGO 0
- AGEN 2
- Target Price
- CGO N/A
- AGEN $14.50
- AVG Volume (30 Days)
- CGO 34.7K
- AGEN 431.2K
- Earning Date
- CGO 01-01-0001
- AGEN 11-11-2025
- Dividend Yield
- CGO 9.25%
- AGEN N/A
- EPS Growth
- CGO N/A
- AGEN N/A
- EPS
- CGO N/A
- AGEN N/A
- Revenue
- CGO N/A
- AGEN $101,706,000.00
- Revenue This Year
- CGO N/A
- AGEN $60.49
- Revenue Next Year
- CGO N/A
- AGEN N/A
- P/E Ratio
- CGO N/A
- AGEN N/A
- Revenue Growth
- CGO N/A
- AGEN N/A
- 52 Week Low
- CGO $7.90
- AGEN $1.38
- 52 Week High
- CGO $10.93
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- CGO 64.06
- AGEN 45.64
- Support Level
- CGO $12.21
- AGEN $3.78
- Resistance Level
- CGO $12.20
- AGEN $4.38
- Average True Range (ATR)
- CGO 0.15
- AGEN 0.24
- MACD
- CGO -0.00
- AGEN 0.00
- Stochastic Oscillator
- CGO 85.60
- AGEN 47.55
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).